ITOS - צמיחת הכנסות שנתית ב-12 החודשים האחרונים iteostherapeutics.com

iTeos Therapeutics (ITOS) is conducting joint compound trials with a major pharmaceutical behemoth, which shields the business from price wars. The company's revenues are based on partner payments and future royalties from immunotherapy. The rolling annual sales growth rate reflects the development dynamics, where the current mark is -84.50. This chart confirms the power of the TIGIT and EOS platform, which creates combined methods for tumor destruction.
פילוחי נתונים אנליטיים מרוכזים עבור iTeos Therapeutics Inc (ITOS)

This metric measures the percentage change in total revenue over the last 12 months, allowing short-term market fluctuations to be decoupled from the sustainable growth of the business's fundamental value. For iTeos Therapeutics (ITOS), whose operations are focused on clinical trials without marketed products, the year-over-year dynamics of core revenue over a rolling 12-month period reflect the effectiveness of the strategic partnership with GSK and the stability of capital inflows.